Regenicin (Regenicin) ROE % Adjusted to Book Value : 0.00% (As of Mar. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Regenicin ROE % Adjusted to Book Value?

Regenicin's ROE % for the quarter that ended in Mar. 2023 was 0.00%. Regenicin's PB Ratio for the quarter that ended in Mar. 2023 was N/A. Regenicin's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2023 was N/A.

Regenicin ROE % Adjusted to Book Value Historical Data

The historical data trend for Regenicin's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin ROE % Adjusted to Book Value Chart

Regenicin Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

Regenicin Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Regenicin's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Regenicin's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenicin's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenicin's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Regenicin's ROE % Adjusted to Book Value falls into.

Regenicin ROE % Adjusted to Book Value Calculation

Regenicin's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Regenicin's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Regenicin ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Regenicin's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenicin (Regenicin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 High Court, Little Falls, NJ, USA, 07424

Website

https://www.regenicin.com

Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines